These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1450 related items for PubMed ID: 12860485

  • 1. Insulin glargine: a systematic review of a long-acting insulin analogue.
    Wang F, Carabino JM, Vergara CM.
    Clin Ther; 2003 Jun; 25(6):1541-77, discussion 1539-40. PubMed ID: 12860485
    [Abstract] [Full Text] [Related]

  • 2. Comparison of insulin glargine and NPH insulin in the treatment of type 2 diabetes: a review of clinical studies.
    Duckworth W, Davis SN.
    J Diabetes Complications; 2007 Jun; 21(3):196-204. PubMed ID: 17493554
    [Abstract] [Full Text] [Related]

  • 3. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
    Semlitsch T, Engler J, Siebenhofer A, Jeitler K, Berghold A, Horvath K.
    Cochrane Database Syst Rev; 2020 Nov 09; 11(11):CD005613. PubMed ID: 33166419
    [Abstract] [Full Text] [Related]

  • 4. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients.
    Riddle MC, Rosenstock J, Gerich J, Insulin Glargine 4002 Study Investigators.
    Diabetes Care; 2003 Nov 09; 26(11):3080-6. PubMed ID: 14578243
    [Abstract] [Full Text] [Related]

  • 5. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group.
    Yki-Järvinen H, Dressler A, Ziemen M, HOE 901/300s Study Group.
    Diabetes Care; 2000 Aug 09; 23(8):1130-6. PubMed ID: 10937510
    [Abstract] [Full Text] [Related]

  • 6. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.
    Hollander P, Cooper J, Bregnhøj J, Pedersen CB.
    Clin Ther; 2008 Nov 09; 30(11):1976-87. PubMed ID: 19108786
    [Abstract] [Full Text] [Related]

  • 7. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial.
    Barnett AH, Burger J, Johns D, Brodows R, Kendall DM, Roberts A, Trautmann ME.
    Clin Ther; 2007 Nov 09; 29(11):2333-48. PubMed ID: 18158075
    [Abstract] [Full Text] [Related]

  • 8. Insulin glargine.
    Campbell RK, White JR, Levien T, Baker D.
    Clin Ther; 2001 Dec 09; 23(12):1938-57; discussion 1923. PubMed ID: 11813930
    [Abstract] [Full Text] [Related]

  • 9. Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting insulin analog at mealtime: a 3-month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime.
    Rossetti P, Pampanelli S, Fanelli C, Porcellati F, Costa E, Torlone E, Scionti L, Bolli GB.
    Diabetes Care; 2003 May 09; 26(5):1490-6. PubMed ID: 12716810
    [Abstract] [Full Text] [Related]

  • 10. Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine.
    Warren E, Weatherley-Jones E, Chilcott J, Beverley C.
    Health Technol Assess; 2004 Nov 09; 8(45):iii, 1-57. PubMed ID: 15525480
    [Abstract] [Full Text] [Related]

  • 11. Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy.
    Fulcher GR, Gilbert RE, Yue DK.
    Intern Med J; 2005 Sep 09; 35(9):536-42. PubMed ID: 16105155
    [Abstract] [Full Text] [Related]

  • 12. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group.
    Rosenstock J, Park G, Zimmerman J, U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group.
    Diabetes Care; 2000 Aug 09; 23(8):1137-42. PubMed ID: 10937511
    [Abstract] [Full Text] [Related]

  • 13. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
    Robbins DC, Beisswenger PJ, Ceriello A, Goldberg RB, Moses RG, Pagkalos EM, Milicevic Z, Jones CA, Sarwat S, Tan MH.
    Clin Ther; 2007 Nov 09; 29(11):2349-64. PubMed ID: 18158076
    [Abstract] [Full Text] [Related]

  • 14. Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial.
    Esposito K, Ciotola M, Maiorino MI, Gualdiero R, Schisano B, Ceriello A, Beneduce F, Feola G, Giugliano D.
    Ann Intern Med; 2008 Oct 21; 149(8):531-9. PubMed ID: 18936501
    [Abstract] [Full Text] [Related]

  • 15. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen.
    Russell-Jones D, Simpson R, Hylleberg B, Draeger E, Bolinder J.
    Clin Ther; 2004 May 21; 26(5):724-36. PubMed ID: 15220016
    [Abstract] [Full Text] [Related]

  • 16. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes.
    Janka HU, Plewe G, Riddle MC, Kliebe-Frisch C, Schweitzer MA, Yki-Järvinen H.
    Diabetes Care; 2005 Feb 21; 28(2):254-9. PubMed ID: 15677775
    [Abstract] [Full Text] [Related]

  • 17. Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven Phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus.
    Mullins P, Sharplin P, Yki-Jarvinen H, Riddle MC, Haring HU.
    Clin Ther; 2007 Aug 21; 29(8):1607-19. PubMed ID: 17919543
    [Abstract] [Full Text] [Related]

  • 18. Dosing of insulin glargine in the treatment of type 2 diabetes.
    Barnett A.
    Clin Ther; 2007 Jun 21; 29(6):987-99. PubMed ID: 17692716
    [Abstract] [Full Text] [Related]

  • 19. Combination of oral antidiabetic agents with basal insulin versus premixed insulin alone in randomized elderly patients with type 2 diabetes mellitus.
    Janka HU, Plewe G, Busch K.
    J Am Geriatr Soc; 2007 Feb 21; 55(2):182-8. PubMed ID: 17302653
    [Abstract] [Full Text] [Related]

  • 20. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial.
    Fritsche A, Schweitzer MA, Häring HU, 4001 Study Group.
    Ann Intern Med; 2003 Jun 17; 138(12):952-9. PubMed ID: 12809451
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 73.